{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IPI-493&page=2", "query": { "intervention": "IPI-493", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IPI-493&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T20:25:40.713Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00047047", "title": "Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "tanespimycin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00047047" }, { "nct_id": "NCT00093496", "title": "Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer", "Stage III Ovarian Epithelial Cancer", "Stage IV Ovarian Epithelial Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2007-10", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093496" }, { "nct_id": "NCT00087386", "title": "Tanespimycin in Treating Patients With Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage III Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-10", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087386" }, { "nct_id": "NCT00514371", "title": "A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2007-08", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 11, "location_summary": "Berkeley, California • San Francisco, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514371" }, { "nct_id": "NCT00606814", "title": "Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "IPI-504, docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2007-12", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-03-06", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606814" }, { "nct_id": "NCT01427946", "title": "Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "IPI-504", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2011-07", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 5, "location_summary": "Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01427946" }, { "nct_id": "NCT00119236", "title": "17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00119236" }, { "nct_id": "NCT01193491", "title": "Dose Escalation of IPI-493 in Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "IPI-493", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Infinity Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2010-06", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2015-04-15", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • Houston, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193491" }, { "nct_id": "NCT00004075", "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-08-03", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004075" }, { "nct_id": "NCT00773344", "title": "Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2005-12", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-09-25T20:25:40.713Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • New York, New York", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00773344" } ] }